Literature DB >> 1747956

Autoantibodies against Forssman glycolipids in Graves' disease and Hashimoto's thyroiditis.

T Ariga1, T Yoshida, T Mimori, R K Yu.   

Abstract

Sera from patients with Graves' disease and Hashimoto's thyroiditis have been shown to react with the Forssman glycolipid antigen (Gb5) using the techniques of high performance thin-layer chromatography (HPTLC) immunostaining and ELISA. Human monoclonal antibodies (MoAbs) have been prepared by fusion of human myeloma with peripheral lymphocytes from patients with Graves' disease. A MoAb, TRMo-4, reacted strongly and specifically with Gb5. These results suggest that anti-Forssman antibody may be involved in the pathogenesis of these autoimmune diseases. The detection of anti-Forssman glycolipid antibody may provide a useful means for clinical diagnosis and therapy.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1747956      PMCID: PMC1554196          DOI: 10.1111/j.1365-2249.1991.tb02957.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  46 in total

1.  Binding of N-acetylgalactosamine-containing compounds by a human IgM paraprotein.

Authors:  M Naiki; D M Marcus
Journal:  J Immunol       Date:  1977-08       Impact factor: 5.422

2.  Studies on heterophile antibodies in rheumatoid arthritis.

Authors:  T Nishimaki; K Kano; F Milgrom
Journal:  Arthritis Rheum       Date:  1978 Jul-Aug

3.  Forssman-like antibody levels in sera of patients with lung cancer.

Authors:  H Kitamura; P Levine; P J Cheng; R A Egeli; Y P Liu; R A Good; N K Day
Journal:  Cancer Res       Date:  1979-08       Impact factor: 12.701

4.  Humoral immunity in Graves' disease.

Authors:  J M McKenzie; M Zakarija; A Sato
Journal:  Clin Endocrinol Metab       Date:  1978-03

5.  Abnormal adenylate cyclase activity and altered membrane gangliosides in thyroid cells from patients with Graves' disease.

Authors:  G Lee; E F Grollman; S M Aloj; L D Kohn; R J Winand
Journal:  Biochem Biophys Res Commun       Date:  1977-07-11       Impact factor: 3.575

6.  Reaction of antibodies that cause paroxysmal cold hemoglobinuria (PCH) with globoside and Forssman glycosphingolipids.

Authors:  G A Schwarting; S K Kundu; D M Marcus
Journal:  Blood       Date:  1979-02       Impact factor: 22.113

Review 7.  Bifunctional role of glycosphingolipids. Modulators for transmembrane signaling and mediators for cellular interactions.

Authors:  S Hakomori
Journal:  J Biol Chem       Date:  1990-11-05       Impact factor: 5.157

8.  Antiglycolipid autoantibody detected in the sera from systemic lupus erythematosus patients.

Authors:  T Hirano; H Hashimoto; Y Shiokawa; M Iwamori; Y Nagai; M Kasai; Y Ochiai; K Okumura
Journal:  J Clin Invest       Date:  1980-12       Impact factor: 14.808

9.  Complement fixation antibodies to glycosphingolipids in sera of rare blood group p and Pk phenotypes.

Authors:  M Kato; S Kubo; M Naiki
Journal:  J Immunogenet       Date:  1978-02

10.  Isoantigenic expression of Forssman glycolipid in human gastric and colonic mucosa: its possible identity with "A-like antigen" in human cancer.

Authors:  S Hakomori; S M Wang; W W Young
Journal:  Proc Natl Acad Sci U S A       Date:  1977-07       Impact factor: 11.205

View more
  3 in total

Review 1.  Unlocking the immunological mechanisms of orbital inflammation in thyroid eye disease.

Authors:  M Ludgate; G Baker
Journal:  Clin Exp Immunol       Date:  2002-02       Impact factor: 4.330

2.  Atomic-resolution conformational analysis of the GM3 ganglioside in a lipid bilayer and its implications for ganglioside-protein recognition at membrane surfaces.

Authors:  Mari L DeMarco; Robert J Woods
Journal:  Glycobiology       Date:  2008-12-04       Impact factor: 4.313

3.  Expression of GBGT1 is epigenetically regulated by DNA methylation in ovarian cancer cells.

Authors:  Francis Jacob; Megan P Hitchins; André Fedier; Kevin Brennan; Sheri Nixdorf; Neville F Hacker; Robyn Ward; Viola A Heinzelmann-Schwarz
Journal:  BMC Mol Biol       Date:  2014-10-07       Impact factor: 2.946

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.